NeuBase Therapeutics, Inc.
NBSE · NASDAQ
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | -0.56 | 0.12 | 0.05 |
| FCF Yield | -229.76% | -20.61% | -7.67% | -8.23% |
| EV / EBITDA | 0.13 | -2.01 | -6.80 | -1.16 |
| Quality | ||||
| ROIC | -115.70% | -44.27% | -53.92% | -260.65% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.74 | 0.62 | 0.11 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -45.15% | -77.76% | -236.27% | 64.20% |
| Safety | ||||
| Net Debt / EBITDA | 0.52 | 1.79 | 1.85 | 0.38 |
| Interest Coverage | -1,385.55 | -821.70 | -2,220.83 | -204.24 |
| Efficiency | ||||
| Inventory Turnover | -9.89 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -569.75 | -1,146.58 | -1,958.69 | -4,199.99 |